NRIX vs PH · rev $54.5M vs P/E 28, rev $19.85B
Nurix Therapeutics Inc (NRIX) versus Parker-Hannifin Corporation (PH) — a side-by-side from cached financials, not a winner call.
Nurix Therapeutics Inc (NRIX) is a biotechnology company listed on NASDAQ.
Parker-Hannifin Corporation (PH) is a specialty industrial machinery company listed on US.
Latest reported NRIX revenue for 2024-11-30 was $54.5M. Net income was -$193.6M. Revenue was down 29.1% from 2023-11-30 to 2024-11-30. NRIX currently screens at market cap $1.77B.
Latest reported PH revenue for 2025-06-30 was $19.85B. Net income was $3.53B. PH currently screens at market cap $91.89B and trailing P/E 27.7.
NRIX currently screens at market cap $1.77B. PH currently screens at market cap $91.89B and trailing P/E 27.7.
Not investment advice. Open the NRIX and PH stock pages for the full models.
Not investment advice.